Mupirocin (Pseudomonic Acid A)
| (myoo-PIHR-oh-sin) |
| Bactroban |
| Class: Topical/anti-infective |
Action Inhibits bacterial protein synthesis.
Indications Topical treatment of impetigo caused by Staphylococcus aureus, Staphylococcus pyogenes, Streptococci, and Bacillus hemolyticus.
Contraindications Standard considerations.
Route/DosageADULTS: Topical Apply tid for 3–5 days.
Interactions None well documented.
Lab Test Interferences None well documented.
Adverse ReactionsDERM: Burning; stinging; pain; rash; itching; contact dermatitis.
PrecautionsPregnancy: Category B. Lactation: Undetermined. Hypersensitivity: Chemical irritation may occur.
| PATIENT CARE CONSIDERATIONS |
|
Administration/Storage- Apply topically only; avoid contact with eyes and mucous membranes. Treated area may be covered with gauze dressing.
- Wash hands before and after application.
Assessment/Interventions- Obtain patient history, including drug history and any known allergies.
- Assess for signs of superinfection (bacterial or fungal overgrowth of nonsusceptible organisms).
- Assess for therapeutic response: decrease in size and number of lesions.
- If a skin reaction develops, discontinue therapy, wash affected area and notify physician.
Patient/Family Education- Warn the patient to avoid contact of drug with eyes and mucous membranes.
- Instruct patient to wash hands before and after application.
- Tell patient to inform physician if no improvement is seen within 3–5 days or if condition worsens.
- Advise patient to keep fingernails well trimmed to prevent scratching.
- Review with patient and family appropriate hygiene measures to prevent spread of impetigo.
- Instruct patient to report these symptoms to physician: burning, stinging, pain, nausea, tenderness, swelling, rash, dry skin or increased exudate.
Popularity: 3% [?]